TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29174612
Drug: Antituberculosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculosis treatment
Study: 29176494
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) dosing between birth and 6 months (average 1882 LU/kg per meal, range: 492-3727)
Study: 29176494
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) dosing between 6 and 12 months (mean 1842 LU/kg per meal, range: 313-3612)
Study: 29176494
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of proton pump inhibitors (PPIs) exclusively
Study: 29176494
Drug: Higher PERT
Normalized name: Pert Plus Dandruff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher PERT dosing strategy
Study: 29177070
Drug: MIS416 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MIS416 treatment for 12 weeks
Study: 29177070
Drug: MIS416 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MIS416 treatment
Study: 29177094
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic combined with dacarbazine (up to 24 doses of MAGE-A3 immunotherapeutic and eight doses of dacarbazine)
Study: 29177471
Drug: Baseline subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline subcutaneous adipocyte volume
Study: 29177699
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 at 25 mg
Study: 29177699
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 at 50 mg
Study: 29177699
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 at 100 mg
Study: 29178102
Drug: Fluorouracil-based chemotherapy
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based chemotherapy
Study: 29179674
Drug: suPAR levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR levels ≥3.00 ng/ml
Study: 29179751
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (45-50.4 GyE in 1.8 GyE fractions 5-6 times per week)
Study: 29180545
Drug: Clinical pharmacist-led
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist-led medication therapy management (MTM) service enhanced by a clinical decision support system (CDSS) and pharmacogenomics (PGx) testing.
Study: 29180633
Drug: Adaptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive therapy using patient-specific tumor dynamics
Study: 29180633
Drug: Standard abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard abiraterone dosing
Study: 29182496
Drug: BGJ398 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles)
Study: 29182729
Drug: Opioids (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (morphine equivalent dose given 24 hours prior to extubation)
Study: 29183928
Drug: Normothermic machine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normothermic machine perfusion of the liver (NMP-L) following a period of static cold storage.
Study: 29184781
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with coordinated combined chemotherapy
Study: 29185557
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV alteplase (0.6 mg/kg)
Study: 29185557
Drug: Standard-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose IV alteplase (0.9 mg/kg)
Study: 29185786
Drug: Low exposure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight)
Study: 29185786
Drug: High exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)
Study: 29188387
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg q.d.
Study: 29188408
Drug: Demcizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demcizumab (5 mg/kg)
Study: 29188408
Drug: Demcizumab (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demcizumab (2.5, 5.0, and 7.5 mg/kg)
Study: 29188408
Drug: Demcizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demcizumab (5 mg/kg q3-weekly ×4)
Study: 29188469
Drug: Merestinib (type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merestinib (type II MET kinase inhibitor)
Study: 29188469
Drug: Emibetuzumab (bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emibetuzumab (bivalent anti-MET antibody)
Study: 29188469
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Merestinib and Emibetuzumab
Study: 29189665
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) of busulfan
Study: 29189665
Drug: Initial busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial busulfan dose based on age/weight
Study: 29189950
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care program using a foam stick (Period 1)
Study: 29189950
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care program using a foam stick and tooth brushing with aspiration (Period 2)
Study: 29189950
Drug: Cost assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost assessment of the oral care program
Study: 29191334
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for secondary mitral regurgitation
Study: 29191916
Drug: Duvelisib 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib 8 to 100 mg twice daily (MTD determined as 75 mg twice daily)
Study: 29191916
Drug: Duvelisib 25
Normalized name: duvelisib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib 25 or 75 mg twice daily continuously
Study: 29193547
Drug: telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine 600 mg/day from gestation 28-32 weeks to 3-4 weeks postpartum
Study: 29193547
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antiviral agent)
Study: 29194623
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation plus perioperative SOX chemotherapy
Study: 29196412
Drug: Vadastuximab talirine
Normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadastuximab talirine IV at 40 µg/kg
Study: 29196412
Drug: Vadastuximab talirine
Normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadastuximab talirine IV at 5-60 µg/kg or 20 µg/kg on days 1 and 4 of 21-day cycles
Study: 29197547
Drug: 270 μg
Normalized name: G 207
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 μg of aerosolized albuterol sulfate administered with a metered dose inhaler with space chamber
Study: 29198079
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin and naproxen sodium
Study: 29198079
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low-dose aspirin only)
Study: 29198845
Drug: Gardening frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardening frequency (monthly or weekly)
Study: 29199321
Drug: ACC-001 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-001 3 µg + QS-21
Study: 29199321
Drug: ACC-001 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-001 10 µg + QS-21
Study: 29201402
Drug: Correct implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct implant knowledge
Study: 29201402
Drug: Intent to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intent to use implant
Study: 29202623
Drug: ANX005, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANX005, administered intravenously once weekly for 4 weeks
Study: 29202623
Drug: First-in-human starting
Normalized name: HUMAN FIRST MILK
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-in-human starting dose of ANX005
Study: 29203493
Drug: Trough concentrations
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trough concentrations of >15 mg/liter
Study: 29203493
Drug: AUC-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC-guided dosing with BestDose Bayesian software
Study: 29203585
Drug: selinexor (3-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: selinexor (3-60 mg/m2)
Study: 29203590
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human IL15 (rhIL15)
Study: 29204958
Drug: Ingenol disoxate
Normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingenol disoxate gel
Study: 29206944
Drug: Kisspeptin-54 (9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-54 (9.6 nmol/kg, one injection)
Study: 29206944
Drug: Kisspeptin-54 (9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-54 (9.6 nmol/kg, two injections at 10 h interval)
Study: 29207608
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) dose adjustment following therapeutic drug monitoring
Study: 29207608
Drug: Genotype-guided BU
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided BU dose adjustments
Study: 29208007
Drug: One session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One session of physical therapy
Study: 29209104
Drug: IL-6R antagonist
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-6R antagonist therapy
Study: 29209458
Drug: Pre-meal almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-meal almond group (PM) - 56 g of almonds consumed before meals
Study: 29209458
Drug: Snack almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack almond group (SN) - 56 g of almonds consumed as a snack between meals
Study: 29209525
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice daily; 3 week continuous treatment cycles)
Study: 29209946
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg every 2 weeks via pen
Study: 29209946
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg every 2 weeks via pen
Study: 29209946
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg every 2 weeks via syringe
Study: 29209946
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg every 2 weeks via syringe
Study: 29210056
Drug: Blood-based precision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-based precision medicine test (ASGES)
Study: 29210351
Drug: Malaria treatment
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria treatment during pregnancy, specific intervention details not provided.
Study: 29210443
Drug: ACC-001 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-001 3 µg + QS-21 adjuvant (50 µg)
Study: 29210443
Drug: ACC-001 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-001 10 µg + QS-21 adjuvant (50 µg)
Study: 29210791
Drug: Closed-loop control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase I
Study: 29210791
Drug: Closed-loop control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase II
Study: 29211618
Drug: Regimen DD4A
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy
Study: 29211678
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with AAV vector (5×10 dose)
Study: 29211678
Drug: Before vector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before vector administration
Study: 29211678
Drug: After vector
Approvals — FDA: no, EMA: no, PMDA: no
Description: After vector administration
Study: 29211870
Drug: Denosumab (fixed-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (fixed-dose, cumulative dose 47 to 98 mg/kg for 1.3 to 4 years)
Study: 29211870
Drug: Denosumab (fixed-dose)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (fixed-dose)
Study: 29212544
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin daily
Study: 29212734
Drug: Neoadjuvant GTX
Normalized name: toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant GTX (gemcitabine 750 mg/m², docetaxel, capecitabine)
Study: 29213243
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) efficacy on CHF patients
Study: 29213269
Drug: ME-TRAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-TRAP and EPI vaccines
Study: 29213281
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside (mean dose 1100 mg, with some patients receiving above 1000 mg)
Study: 29214034
Drug: Abatacept (~10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (~10 mg/kg/month)
Study: 29216353
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy in transwomen
Study: 29216353
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy in transmen
Study: 29216400
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg bd
Study: 29217288
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed disease progression, unacceptable toxicity, or other criterion for withdrawal.
Study: 29217776
Drug: Melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 200 mg/m
Study: 29566106
Drug: Avelumab treatment
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab treatment
Study: 29220505
Drug: ab+/ins- (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab+/ins- (antibody positive/insulin negative)
Study: 29220505
Drug: ab+/ins+ (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab+/ins+ (antibody positive/insulin positive)
Study: 29220505
Drug: ab-/ins- (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab-/ins- (antibody negative/insulin negative)
Study: 29222199
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks
Study: 29222649
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (two 220 mg capsules of zinc sulfate per day for 3 months)
Study: 29223443
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/d) for 18 months
Study: 29223912
Drug: Maternal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal buprenorphine dose at delivery
Study: 29224506
Drug: High-dose AAV5-hFVIII-SQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AAV5-hFVIII-SQ
Study: 29225903
Drug: Prasugrel or
Normalized name: prasugrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel or ticagrelor as loading P2Y inhibitor
Study: 29225903
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with optional glycoprotein IIb/IIIa inhibitor treatment
Study: 29226268
Drug: Latanoprost (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (one drop daily at bedtime for seven days)
Study: 29226797
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) CAR T-cell therapy
Study: 29229365
Drug: Contralateral control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral control area of spongy alveolar bone without treatment
Study: 29229594
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) and nivolumab (Nivo) combination treatment
Study: 29230323
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA treatment
Study: 29230539
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) at a dose of 0.4 mg/kg
Study: 29233163
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous bone marrow mesenchymal stem cells (BM-MSCs)
Study: 29233751
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with intravenous immunoglobulin
Study: 29233792
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) supplementation (2 × 600mg, twice daily, for 30 days)
Study: 29234503
Drug: Enteral cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral cholecalciferol loading dose (10,000 IU/kg, maximum of 400,000 IU)
Study: 29234955
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of treatment measures of mental health status, work ability, generalized self-efficacy, and expectations of future work ability.
Study: 29234955
Drug: Expectancy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy of future work ability improvement or positivity from before to the end of treatment.
Study: 29235365
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy with 20 mg azilsartan, 5 mg amlodipine, and 12.5 mg hydrochlorothiazide (AZL/AML/HCTZ)
Study: 29235365
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy with AZL/AML/HCTZ
Study: 29235365
Drug: AZL/AML therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL/AML therapy
Study: 29238851
Drug: Mocetinostat 90
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 90 mg TIW + gemcitabine 1000 mg/m²
Study: 29239002
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg osimertinib once daily
Study: 29239953
Drug: TXA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (1 g intravenously)
Study: 29240542
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal
Study: 29241084
Drug: Capecitabine 825
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m² combined with sorafenib and radiotherapy (45 Gy in 25 fractions over 5 weeks)
Study: 29241084
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I study to establish maximum tolerated dose
Study: 29241979
Drug: Acalabrutinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib (100 mg twice per day)
Study: 29242852
Drug: Nonmyeloablative mMUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative mMUD BMT with high-dose posttransplantation cyclophosphamide (PTCy)
Study: 29243075
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin q.d. for 8 weeks
Study: 29243168
Drug: Symptoms of
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptoms of metastatic prostate cancer and treatment side effects
Study: 29243222
Drug: Durvalumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (anti-PD-L1 monoclonal antibody)
Study: 29243287
Drug: Dabrafenib 300
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 300 mg BID
Study: 29243287
Drug: Dabrafenib 300
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 300 mg